Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Decline in Short Interest

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a significant decline in short interest in November. As of November 15th, there was short interest totalling 8,400 shares, a decline of 43.2% from the October 31st total of 14,800 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average trading volume of 20,500 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a research report on Friday, November 22nd.

Xenetic Biosciences Price Performance

XBIO stock opened at $4.20 on Friday. The business’s 50-day moving average is $3.92 and its two-hundred day moving average is $3.93. The firm has a market capitalization of $6.47 million, a P/E ratio of -1.55 and a beta of 2.25. Xenetic Biosciences has a 1 year low of $2.78 and a 1 year high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million. On average, analysts expect that Xenetic Biosciences will post -1.01 EPS for the current year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.